人胰岛淀粉样多肽聚集上调线粒体胆固醇转运蛋白StAR并诱导β细胞线粒体功能障碍
研究探讨人胰岛淀粉样多肽(hIAPP)聚集毒性中StAR的作用。在非糖尿病供体胰岛及hIAPP转基因小鼠胰岛的淀粉样条件下,StAR表达随淀粉样形成显著增加,且主要定位于β细胞线粒体组分。StAR上调与线粒体葡萄糖刺激呼吸下降和细胞死亡增加相关,提示StAR在2型糖尿病β细胞病理生理中起作用。
要点
- hIAPP聚集在体外和转基因小鼠胰岛中均使StAR表达显著增加。
- StAR主要表达于β细胞,淀粉样诱导的StAR增加特异见于线粒体组分。
- StAR上调与线粒体葡萄糖刺激呼吸下降及细胞死亡增加相关。
核心结论
- StAR在2型糖尿病β细胞中可能具有病理生理作用,其在胰岛淀粉样沉积条件下上调可导致线粒体功能障碍。
研究设计与样本
- 非糖尿病供体人胰岛在淀粉样条件下培养,检测StAR表达。
- 表达淀粉样hIAPP的转基因小鼠胰岛与表达非淀粉样胰岛淀粉样多肽的非转基因同窝小鼠胰岛在淀粉样条件下培养,加或不加淀粉样抑制剂,检测StAR表达。
- 比较转基因与非转基因小鼠胰岛的总胆固醇、线粒体胆固醇、线粒体功能和细胞活力/死亡。
- 检测StAR在胰岛细胞中的定位及细胞内定位。
主要发现
- StAR在人胰岛mRNA和蛋白水平存在,体外淀粉样形成时表达显著增加。
- hIAPP转基因小鼠胰岛中StAR表达呈淀粉样依赖。
- StAR主要表达于β细胞,淀粉样诱导的StAR蛋白增加特异见于线粒体组分。
- 淀粉样条件下培养的非转基因与hIAPP转基因小鼠胰岛总胆固醇和线粒体胆固醇含量无变化。
- StAR表达增加与线粒体葡萄糖刺激呼吸下降和细胞死亡增加相关。
临床怎么用
- StAR及其介导的线粒体胆固醇转运可能作为2型糖尿病β细胞功能障碍的潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Loss of islet beta cell function and mass are critical in the pathogenesis of type 2 diabetes, a disease in which ~90% of individuals exhibit islet amyloid deposition. Amyloid deposits comprise the normal beta cell secretory product, human islet amyloid polypeptide (hIAPP), the aggregation of which is toxic to beta cells. While the underlying mechanism(s) for toxicity remain unknown, it is likely to involve mitochondrial dysfunction. We have shown that the mitochondrial cholesterol transport protein, steroidogenic acute regulatory protein (StAR), is upregulated in beta cells following amyloid deposition. Here, we examined the role of StAR in the toxicity of islet amyloidosis. METHODS: Human islets from non-diabetic donors were cultured under amyloidogenic conditions and StAR expression was examined. StAR expression was also determined in islets isolated from transgenic mice expressing amyloidogenic hIAPP or non-transgenic littermates expressing non-amyloidogenic islet amyloid polypeptide, cultured under amyloidogenic conditions with or without the addition of an amyloid inhibitor. Total islet cholesterol content, mitochondrial cholesterol content, mitochondrial function and cell viability/death were compared in transgenic hIAPP and non-transgenic islets cultured in amyloidogenic conditions. Additionally, StAR localisation to islet cells, as well as its intracellular localisation, was examined. RESULTS: StAR was present in human islets at the mRNA and protein level, and expression increased significantly with amyloid formation in vitro. Further, in hIAPP transgenic mouse islets, StAR expression was amyloid-dependent. StAR was predominantly expressed in beta cells, and the amyloid-induced increase in StAR protein was found specifically in the mitochondrial fraction. While total and mitochondrial cholesterol content was unchanged between non-transgenic and hIAPP transgenic mouse islets cultured under amyloidogenic conditions, increased StAR expression was associated with decreased mitochondrial glucose-stimulated respiration and increased cell death. CONCLUSIONS/INTERPRETATION: These findings are consistent with StAR having a pathophysiological role in the beta cell in type 2 diabetes, where its upregulation under conditions of islet amyloid deposition could contribute to mitochondrial dysfunction.
引用
- Hogan MF, Akter R, Aplin AC, et al. Human islet amyloid polypeptide aggregation upregulates the mitochondrial cholesterol transport protein StAR and induces mitochondrial dysfunction in beta cells. Diabetologia. 2026. PMID: 42159696. doi:10.1007/s00125-026-06749-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。